GSK (GSK) Expected to Announce Quarterly Earnings on Wednesday

GSK (NYSE:GSK) is expected to announce its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect the company to announce earnings of $0.66 per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 6:00 AM ET.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, October 29th. The pharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.22. GSK had a net margin of 17.16% and a return on equity of 48.64%. The company had revenue of $11.35 billion during the quarter, compared to analysts’ expectations of $8.21 billion. During the same period in the previous year, the company earned $0.50 EPS. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. On average, analysts expect GSK to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

GSK Stock Up 1.1%

GSK stock opened at $50.89 on Wednesday. The company has a market capitalization of $103.74 billion, a P/E ratio of 14.38, a PEG ratio of 1.48 and a beta of 0.45. The firm has a 50 day simple moving average of $48.76 and a 200-day simple moving average of $44.04. The company has a current ratio of 0.84, a quick ratio of 0.55 and a debt-to-equity ratio of 0.95. GSK has a twelve month low of $32.38 and a twelve month high of $51.46.

Insider Activity at GSK

In other GSK news, major shareholder Plc Gsk acquired 1,470,000 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an average cost of $19.00 per share, with a total value of $27,930,000.00. Following the acquisition, the insider owned 18,245,691 shares in the company, valued at approximately $346,668,129. This represents a 8.76% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 10.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On GSK

Hedge funds and other institutional investors have recently modified their holdings of the stock. BI Asset Management Fondsmaeglerselskab A S lifted its position in GSK by 28.2% during the 2nd quarter. BI Asset Management Fondsmaeglerselskab A S now owns 121,249 shares of the pharmaceutical company’s stock valued at $4,656,000 after acquiring an additional 26,685 shares during the period. AQR Capital Management LLC grew its stake in shares of GSK by 84.4% in the first quarter. AQR Capital Management LLC now owns 40,239 shares of the pharmaceutical company’s stock worth $1,559,000 after acquiring an additional 18,420 shares during the last quarter. Brighton Jones LLC purchased a new stake in GSK during the 4th quarter valued at about $528,000. Captrust Financial Advisors increased its position in shares of GSK by 11.0% during the second quarter. Captrust Financial Advisors now owns 85,080 shares of the pharmaceutical company’s stock valued at $3,267,000 after acquiring an additional 8,432 shares in the last quarter. Finally, SkyView Investment Advisors LLC bought a new stake in shares of GSK in the 2nd quarter worth $303,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on GSK shares. HSBC reaffirmed a “reduce” rating on shares of GSK in a research report on Wednesday, December 10th. Barclays lowered GSK from an “equal weight” rating to an “underweight” rating in a research note on Tuesday, January 6th. Morgan Stanley reaffirmed an “underweight” rating on shares of GSK in a research note on Wednesday, January 14th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of GSK in a research report on Friday, January 16th. Finally, Cfra set a $53.00 price target on shares of GSK in a report on Thursday, October 30th. Two investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus target price of $44.13.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.